A retrospective, multicenter study of Melphalan/HDS in patients with ocular melanoma metastasized to the liver

Trial Profile

A retrospective, multicenter study of Melphalan/HDS in patients with ocular melanoma metastasized to the liver

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Melphalan (Primary)
  • Indications Liver metastases; Uveal melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Mar 2017 New trial record
    • 21 Feb 2017 According to Delcath Systems media release, the findings were reported at the Regional Cancer Therapies 12th International Symposium in an oral presentation. The presentation was led by Dr. Alexandra Gangi of the Moffitt Cancer Center.
    • 21 Feb 2017 According to Delcath Systems media release, patients treated at either the Moffitt Cancer Center or the University Hospital Southampton.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top